Heritage Investors Management Corp raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 422,225 shares of the biopharmaceutical company’s stock after purchasing an additional 4,958 shares during the quarter. Heritage Investors Management Corp’s holdings in Pfizer were worth $15,073,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Shine Investment Advisory Services Inc. acquired a new position in Pfizer during the 2nd quarter valued at approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new position in Pfizer during the 2nd quarter valued at approximately $103,000. D. Scott Neal Inc. increased its stake in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares in the last quarter. Herndon Capital Management LLC acquired a new position in Pfizer during the 2nd quarter valued at approximately $120,000. Finally, Lipe & Dalton increased its stake in Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 69.75% of the company’s stock.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Insiders have sold 29,450 shares of company stock worth $1,065,220 over the last three months. 0.06% of the stock is currently owned by insiders.
Shares of Pfizer Inc. (NYSE PFE) opened at $36.86 on Friday. The company has a market cap of $219,710.00, a price-to-earnings ratio of 22.61, a PEG ratio of 2.46 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $37.35.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the prior year, the firm posted $0.61 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. sell-side analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a yield of 3.69%. Pfizer’s dividend payout ratio is 78.53%.
TRADEMARK VIOLATION WARNING: This piece was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/07/pfizer-inc-pfe-holdings-lifted-by-heritage-investors-management-corp.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
What are top analysts saying about Pfizer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer and related companies.